单胺氧化酶抑制剂及其药理意义。
Monoamine oxidase inhibitors and their pharmacological significance.
作者信息
Sandler M
出版信息
Acta Neurol Scand Suppl. 1983;95:37-41. doi: 10.1111/j.1600-0404.1983.tb01515.x.
Abstract
The role of deprenyl, a selective monoamine oxidase B inhibitor, in the treatment of Parkinson's disease has been evaluated with special reference to the multiple pharmacological actions of the monoamine oxidase-inhibitory group of drugs.
摘要
作为一种选择性单胺氧化酶B抑制剂，司来吉兰在治疗帕金森病中的作用已根据单胺氧化酶抑制类药物的多种药理作用进行了评估。
相似文献
1
Monoamine oxidase inhibitors and their pharmacological significance.单胺氧化酶抑制剂及其药理意义。
Acta Neurol Scand Suppl. 1983;95:37-41. doi: 10.1111/j.1600-0404.1983.tb01515.x.
2
R-(-)-deprenyl and parkinsonism.R-(-)-司来吉兰与帕金森病
J Neural Transm Suppl. 1987;25:5-12.
3
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
Acta Neurol Scand Suppl. 1983;95:43-55. doi: 10.1111/j.1600-0404.1983.tb01516.x.
4
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.用左旋司来吉兰治疗的帕金森病患者大脑中的单胺氧化酶活性和单胺代谢
J Neurochem. 1986 May;46(5):1359-65. doi: 10.1111/j.1471-4159.1986.tb01747.x.
5
Deprenyl (selegiline) in the treatment of Parkinson's disease.司来吉兰治疗帕金森病
Acta Neurol Scand Suppl. 1983;95:103-5. doi: 10.1111/j.1600-0404.1983.tb01522.x.
6
Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).接受单胺氧化酶-A（氯吉兰）或单胺氧化酶-B（司来吉兰和帕吉林）炔属抑制剂的个体中痕量胺的差异变化。
J Neural Transm Suppl. 1998;52:39-48. doi: 10.1007/978-3-7091-6499-0_5.
7
Selegiline for Parkinson's disease.司来吉兰用于帕金森病。
Am Fam Physician. 1990 Feb;41(2):589-91.
8
9
Absence of "cheese effect" during deprenyl therapy: some recent studies.司来吉兰治疗期间“奶酪效应”的缺失：一些近期研究
J Neural Transm. 1978;43(3-4):209-15. doi: 10.1007/BF01246957.
10
(-)Deprenyl in the treatment of Parkinson's disease.（-）司来吉兰治疗帕金森病。
Clin Neuropharmacol. 1982;5(2):195-230. doi: 10.1097/00002826-198205020-00004.
Zotero 插件